NCT06724835View on ClinicalTrials.gov

Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T)

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Advanced Breast Cancer
Interventions
DRUG

XKDCT293

Autologous targeted Nectin4 chimeric antigen receptor T cell injection

OTHER

CAR-T cell

Nectin-4-CAR-T

Trial Locations (1)

455000

RECRUITING

AnYang Tumor Hospital, Anyang

All Listed Sponsors
lead

Shenzhen Celconta Life Science Co., Ltd.

INDUSTRY